CreativeOne Wealth LLC boosted its position in DaVita Inc. (NYSE:DVA – Free Report) by 12.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,314 shares of the company’s stock after purchasing an additional 363 shares during the quarter. CreativeOne Wealth LLC’s holdings in DaVita were worth $543,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in DVA. Transcendent Capital Group LLC bought a new position in shares of DaVita in the 3rd quarter worth about $25,000. Blue Trust Inc. lifted its holdings in shares of DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the last quarter. Family Firm Inc. bought a new stake in shares of DaVita in the 2nd quarter worth approximately $43,000. Versant Capital Management Inc grew its stake in shares of DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after buying an additional 155 shares during the last quarter. Finally, Friedenthal Financial bought a new position in DaVita during the 2nd quarter valued at approximately $48,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.
Insider Transactions at DaVita
In related news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 2.00% of the company’s stock.
DaVita Stock Up 0.3 %
DaVita (NYSE:DVA – Get Free Report) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter last year, the business earned $2.85 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. Research analysts anticipate that DaVita Inc. will post 9.71 EPS for the current year.
Analysts Set New Price Targets
A number of research firms have recently commented on DVA. Bank of America increased their target price on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Finally, Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $161.80.
Get Our Latest Research Report on DaVita
DaVita Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- How to Read Stock Charts for Beginners
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.